Login
Navigate Fool.com
Will ECYT beat
the market?

Endocyte, Inc.

NASDAQ: ECYT

Community Rating: 2 Stars: Unattractive

18.15 -0.50 (-2.68%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $18.51
Previous Close $18.65
Daily Range $17.82 - $19.20
52-Week Range $8.18 - $33.70
Market Cap $737.9M
P/E Ratio -37.30
Dividend (Yield) $0.00 (0.0%)
Volume 952,764
Average Daily Volume 1,960,192
Current FY EPS -$0.34

How do you think ECYT
will perform against the market?

Top ECYT Bull/Bear Pitches

 

BuffettJunior1 (< 20)
Submitted December 14, 2011

Endocyte Inc. (ECYT) is a bio-pharmaceutical Company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molec … More

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted April 26, 2011

I can't say I've researched this company exhaustively, but I find the huge bump today to be disproportionate to the catalyst. Endocyte has completed the PRECEDENT phase II study of EC145 in platinum- … More

0 Replies Reply Report this Post

News & Commentary

5 Unlikely Companies Bucking the Biotech Sell-Off

The SPDR S&P Biotech ETF is down 22.4% over the trailing month, but these five biotech stocks are all up. What's their secret?

Big Pharma Failure = Biotech Takeover?

Today's big winner in the biotech space is Endocyte, because of a bit of schadenfreude.

Overall Survival Will Be Critical for Endocyte's Vintafolide

The CHMP decision recommending European approval is great news for Endocyte, but success in the U.S. will require meeting a more stringent standard for efficacy.

Pre-Market Most Active for Mar 28, 2014 : BBRY, COMM, ARIA, ECYT, MNKD, WUBA, SIRI, BAC, SNE, HMC,

Pre-Market Most Active for Mar 28, 2014 : BBRY, COMM, ARIA, ECYT, MNKD, WUBA, SIRI, BAC, SNE, HMC, VZ, NOK

Will Vintafolide Approval Silence Endocyte Bears?

See why the bearish attitude toward Endocyte was wrong, and right.

Better Buy: Clovis Oncology, Inc. or Endocyte, Inc?

Developmental stage oncology companies to consider.

5 of Last Week's Biggest Winners

These five stocks posted double-digit percentage gains.

Endocyte, Inc. Still Has Huge Potential Post-90% Pop

The biggest winner in biotech Friday was Endocyte, with its massive single-day 90% gain. Is there still time for investors to get in?

This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again

Two regulatory actions, four mammoth clinical study updates, and an intriguing immunotherapeutic collaboration, are this week's most important biotech stories.

3 Humongous Health-Care Stocks This Week

March Madness isn't just for basketball. Check out this week's big winners in the health-care world.

See More ECYT News...

Sector

Healthcare

Industry

Drugs

Endocyte, Inc. (ECYT) Description

Endocyte Inc is a biopharmaceutical Company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates or SMDCs and companion imaging diagnose. Website: http://www.endocyte.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks